Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose remimazolam or midazolam combined with propofol for anesthesia induction in total mastectomy
ChiCTR2600123407Phase 4Not yet recruiting
- Sponsor
- Jieyang People's Hospital
- Start
- Apr 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam, midazolam, propofol and sufentanil in breast cancer (3 arms), sponsored by Jieyang People's Hospital. Primary endpoint: Incidence of hypotension during induction. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
remimazolammidazolampropofolsufentanil
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600123407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123407.